VAD-044

DB17697InvestigationalSmall molecule

VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.

Mechanism: Pharmacologically active on RAC-alpha serine/threonine-protein kinase and RAC-beta serine/threonine-protein kinase
Curator reviewed
Also known as: 6-(4-((1S,3S)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one · VAD 044 · VAD044
Code names: ALM-301

Resolves to

Compound

UNIIK2US8HW4TQ

Targets

P31749AKT1P31751AKT2

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with VAD-044, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account